CAV Regimen for R/R Ph- B-ALL

Sponsor
The First Affiliated Hospital of Soochow University
Study ID
NCT05657652
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to investigate the efficacy and safety of cladribine, venetoclax combined with cytarabine and venetoclax (CAV regimen) for relapsed/refractory (R/R) Philadelphia Chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL).

Key Dates

Start date
Oct 1, 2022
Status verified
Dec 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CAV regimen

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: ORR assessment is measured on days 21 from the start of CAV regimen ]

Related Studies